GM-CSF

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial
Zelalem Temesgen, Colleen F Kelley, Frank Cerasoli, Adrian Kilcoyne, Dale Chappell, Cameron Durrant, Omar Ahmed, Gabrielle Chappell, Victoria Catterson, Christopher Polk, Andrew Badley, Vincent C Marconi

Thorax Jul 2022, thoraxjnl-2022-218744; DOI: 10.1136/thoraxjnl-2022-218744
Randomised controlled trial of GM-CSF in critically ill patients with impaired neutrophil phagocytosis
Emma M Pinder, Anthony J Rostron, Thomas P Hellyer, Marie-Helene Ruchaud-Sparagano, Jonathan Scott, James G Macfarlane, Sarah Wiscombe, John D Widdrington, Alistair I Roy, Vanessa C Linnett, Simon V Baudouin, Stephen E Wright, Thomas Chadwick, Tony Fouweather, Jatinder K Juss, Edwin R Chilvers, Susan A Bowett, Jennie Parker, Daniel F McAuley, Andrew Conway Morris, A John Simpson

Thorax Oct 2018, 73 (10) 918-925; DOI: 10.1136/thoraxjnl-2017-211323
Oxidant-induced corticosteroid unresponsiveness in human bronchial epithelial cells
Irene Heijink, Antoon van Oosterhout, Nathalie Kliphuis, Marnix Jonker, Roland Hoffmann, Eef Telenga, Karin Klooster, Dirk-Jan Slebos, Nick ten Hacken, Dirkje Postma, Maarten van den Berge

Thorax Jan 2014, 69 (1) 5-13; DOI: 10.1136/thoraxjnl-2013-203520
Pulmonary alveolar proteinosis: a complete response to GM-CSF therapy
R M Barraclough, A J Gillies

Thorax Aug 2001, 56 (8) 664-665; DOI: 10.1136/thx.56.8.664

Main menu